Loyal

Loyal is a biotech company based in San Francisco that is pioneering the development of longevity drugs for dogs. The company's primary focus is on creating the world's first FDA-approved drugs aimed at extending the healthy lifespan of dogs. Loyal has three distinct products in its pipeline – LOY-001 and LOY-003, designed to prolong the lives of large-breed dogs, and LOY-002, intended for senior dogs weighing 14 pounds or more.

LOY-001, an injectable formulation, works by reducing levels of the hormone IGF-1, which has been linked to the shorter lifespans of larger dog breeds. In early studies, the drug successfully lowered IGF-1 levels in large dogs to those seen in medium-sized dogs. LOY-003 is a pill version of the same formulation for large and giant breeds.

LOY-002 is a pill developed to extend the healthy lifespan of older dogs across nearly all sizes and breeds. Based on promising data from its initial trials, the FDA has determined that LOY-001 has a "reasonable expectation of effectiveness," a significant milestone for the company and the first of its kind for any longevity drug.

Loyal's approach to developing these products involves targeting the underlying mechanisms of aging in dogs, with the aim of reducing or delaying mortality from age-associated diseases, thereby improving the quality of life and extending the overall lifespan of canines. The company's work builds upon decades of research in the field of dog health and longevity.

Loyal anticipates LOY-002 to be available as early as 2025, pending FDA conditional approval. The company also aims to launch LOY-001 and LOY-003 by 2026, subject to regulatory clearances.